

Change of Director’s Interest Notices – Appendix 3Y

MGC Pharmaceuticals Limited (ASX: MXC, ‘MGC Pharma’ or ‘the Company’), provides the Change of Director’s Interest Notice for directors Mr Brett Mitchell and Dr Ross Walker following their participation in the Company’s recent Share Purchase Plan (SPP).

The Company Chairman Mr Mitchell invested the maximum amount permitted under the terms of the SPP being \$30,000, with Non-Executive Director Dr Walker acquiring \$10,000 worth of new shares. Overseas-based directors were ineligible to participate.

The Appendix 3Y’s are attached.

--Ends--

Authorised for issue by the Company Secretary Rachel Kerr, for further information, please contact:

UK IR/Media Advisors

Catherine Leftley/Megan Dennison
St Brides Partners Ltd
+44 (0) 207 236 1177
megan@stbridespartners.co.uk
catherine@stbridespartners.co.uk

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 6382 3390
info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its ‘Seed to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and recent research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana, highlighted the positive impact of using specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. In order to meet the demands of becoming a key global supplier the company is constructing a 15,720m² GMP state of the art facility in Malta.

Follow us through our social media channels



A
S
X

R
E
L
E
A
S
E

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Anthony Mitchell
Date of last notice	2 January 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Brett and Michelle Mitchell <Mitchell Spring Family A/C> Trustee Brett and Michelle Mitchell <Lefthanders Super Fund A/C> Trustee
Date of change	18 March 2020
No. of securities held prior to change	Brett and Michelle Mitchell <Mitchell Spring Family A/C> 20,458,889 Fully Paid Ordinary Shares 5,000,000 Performance Rights Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 6,335,005 Fully Paid Ordinary Shares 5,000,000 Performance Rights Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023
Class	Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number acquired	1,111,110
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$30,000 (\$0.027 per share)
No. of securities held after change	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C> 21,014,444 Fully Paid Ordinary Shares 5,000,000 Performance Rights</p> <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 6,890,560 Fully Paid Ordinary Shares 5,000,000 Performance Rights</p> <p>Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Share Purchase Plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Grant Thomas Walker
Date of last notice	30 January 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ross G T Walker Pty Ltd Director and Shareholder
Date of change	18 March 2020
No. of securities held prior to change	Ross G T Walker Pty Ltd 4,000,000 Fully Paid Ordinary Shares
Class	Fully Paid Ordinary Shares
Number acquired	370,370
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$10,000 (\$0.027 per share)

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	Ross G T Walker Pty Ltd 4,370,370 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Share Purchase Plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.